Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT04666129. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Study identification
- NCT ID
- NCT04666129
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- Abiraterone Drug
- Apalutamide Drug
- Docetaxel Drug
- Methylprednisolone Drug
- Prednisone Drug
- Relugolix Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2021
- Primary completion
- May 27, 2024
- Completion
- May 27, 2024
- Last update posted
- Aug 16, 2025
2021 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Urological Associates of Southern Arizona, P.C. | Tucson | Arizona | 85741 | — |
| Arkansas Urology | Little Rock | Arkansas | 72211 | — |
| Colorodo Clinical Research | Lakewood | Colorado | 80228 | — |
| Chesapeake Urology Research Associates | Baltimore | Maryland | 21204 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| New Jersey Urology | Saddle Brook | New Jersey | 07663 | — |
| Clinical Research Alliance, Inc. | Westbury | New York | 11590 | — |
| Alliance Urology | Greensboro | North Carolina | 27403 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Helios Clinical Research, LLC. | Middleburg Heights | Ohio | 44130 | — |
| Center for Advanced Urology, LLP d/b/a: MidLantic Urology | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Keystone Urology Specialists | Lancaster | Pennsylvania | 17604 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| Urology Associates, P.C. | Nashville | Tennessee | 37209 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Urology San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04666129, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04666129 live on ClinicalTrials.gov.